Pre-targeting with ultra-small nanoparticles: boron carbon dots as drug candidates for boron neutron capture therapy.

Autor: Feiner IVJ; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain. jllop@cicbiomagune.es., Pulagam KR; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain. jllop@cicbiomagune.es., Uribe KB; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain. jllop@cicbiomagune.es., Passannante R; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain. jllop@cicbiomagune.es., Simó C; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain. jllop@cicbiomagune.es., Zamacola K; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain. jllop@cicbiomagune.es., Gómez-Vallejo V; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain. jllop@cicbiomagune.es., Herrero-Álvarez N; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain. jllop@cicbiomagune.es., Cossío U; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain. jllop@cicbiomagune.es., Baz Z; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain. jllop@cicbiomagune.es., Caffarel MM; Biodonostia Health Research Institute, San Sebastian, Spain and IKERBASQUE, Basque Foundation for Science, Bilbao, Spain., Lawrie CH; Biodonostia Health Research Institute, San Sebastian, Spain and IKERBASQUE, Basque Foundation for Science, Bilbao, Spain and Radcliffe Department of Medicine, University of Oxford, Oxford, UK., Vugts DJ; Amsterdam UMC, Vrije Universiteit Amsterdam, Dept. Radiology & Nuclear Medicine, The Netherlands., Rejc L; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain. jllop@cicbiomagune.es and University of Ljubljana, Faculty of Chemistry and Chemical Technology, Večna pot 113, 1000 Ljubljana, Slovenia., Llop J; CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Spain. jllop@cicbiomagune.es and Centro de Investigación Biomédica en Red, Enfermedades Respiratorias - CIBERES, Madrid, Spain.
Jazyk: angličtina
Zdroj: Journal of materials chemistry. B [J Mater Chem B] 2021 Jan 21; Vol. 9 (2), pp. 410-420.
DOI: 10.1039/d0tb01880e
Abstrakt: Boron neutron capture therapy (BNCT) is a promising cancer treatment exploiting the neutron capture capacity and subsequent fission reaction of boron-10. The emergence of nanotechnology has encouraged the development of nanocarriers capable of accumulating boron atoms preferentially in tumour cells. However, a long circulation time, required for high tumour accumulation, is usually accompanied by accumulation of the nanosystem in organs such as the liver and the spleen, which may cause off-target side effects. This could be overcome by using small-sized boron carriers via a pre-targeting strategy. Here, we report the preparation, characterisation and in vivo evaluation of tetrazine-functionalised boron-rich carbon dots, which show very fast clearance and low tumour uptake after intravenous administration in a mouse HER2 (human epidermal growth factor receptor 2)-positive tumour model. Enhanced tumour accumulation was achieved when using a pretargeting approach, which was accomplished by a highly selective biorthogonal reaction at the tumour site with trans-cyclooctene-functionalised Trastuzumab.
Databáze: MEDLINE
Externí odkaz: